Exondys 51

Wave faces key test in bid to challenge Sarepta in DMD
Wave faces key test in bid to challenge Sarepta in DMD
Biopharma Dive
Wave Life Sciences
Sarepta Therapeutics
Exondys 51
Duchenne Muscular Dystrophy
Flag link:
The FDA and Sarepta: a window into the real world of drug regulation
The FDA and Sarepta: a window into the real world of drug regulation
Stat
FDA
regulatory
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Exondys 51
Vyondys 53
Flag link:
Sarepta's Lone Analyst Skeptic Takes On 22 Bulls With Renewed Warnings
Sarepta's Lone Analyst Skeptic Takes On 22 Bulls With Renewed Warnings
Bloomberg
Sarepta Therapeutics
analysts
Duchenne Muscular Dystrophy
Vyondys 53
Exondys 51
Flag link:
Four New Drugs are Around the Corner. Here’s What You Need to Know.
Four New Drugs are Around the Corner. Here’s What You Need to Know.
Xconomy
FDA
drug approvals
AbbVie
Upadacitinib
Exondys 51
Sarepta Therapeutics
Nabriva Therapeutics
lefamulin
Roche
Rozlytrek
Flag link:
Studies Show Sarepta's Exondys 51 Slows Respiratory Decline in Muscular Dystrophy Patients
Studies Show Sarepta's Exondys 51 Slows Respiratory Decline in Muscular Dystrophy Patients
BioSpace
Sarepta Therapeutics
Exondys 51
DMD
Duchenne Muscular Dystrophy
Flag link:
UPDATED: Sarepta's Exondys 51 is not cost-effective, nor particularly beneficial for DMD patients — ICER
UPDATED: Sarepta's Exondys 51 is not cost-effective, nor particularly beneficial for DMD patients — ICER
Endpoints
Duchenne Muscular Dystrophy
ICER
Sarepta Therapeutics
Exondys 51
Flag link:
Down but Not Out: 10 Biggest Drug Trials That Saw Challenges in 2018
Down but Not Out: 10 Biggest Drug Trials That Saw Challenges in 2018
BioSpace
clinical trials
Takeda
Zinfandel Pharmaceuticals
pioglitazone
Alzheimer's disease
Boehringer Ingelheim
BI 409306
Merck
verubecestat
Celgene
MS
ozanimod
Incyte
ID01
melanoma
vTv Therapeutics
azeliragon
Roche
Tecentriq
Exelixis
colorectal cancer
JNJ
atabacestat
Sareptat Therapeutics
DMD
Exondys 51
Alkermes
ALKS-5461
clinical depression
Flag link:
Europe Advisory Panel Rejects Sarepta’s Duchenne Drug Once Again
Europe Advisory Panel Rejects Sarepta’s Duchenne Drug Once Again
Xconomy
Europe
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Exondys 51
eteplirsen
Flag link:
Sarepta’s eteplirsen spurned as European regulators turn thumbs down on controversial Duchenne MD drug
Sarepta’s eteplirsen spurned as European regulators turn thumbs down on controversial Duchenne MD drug
Endpoints
Sarepta Therapeutics
Duchenne Muscular Dystrophy
eteplirsen
Exondys 51
CHMP
Europe
Flag link:
Should Sarepta’s patents be seized by the government? Patient advocates pitch controversial drug pricing proposal
Should Sarepta’s patents be seized by the government? Patient advocates pitch controversial drug pricing proposal
Endpoints
Sarepta Therapeutics
patients
patents
Exondys 51
Duchenne Muscular Dystrophy
Flag link:
Sarepta to seek FDA approval for its second Duchenne’s drug by year’s end
Sarepta to seek FDA approval for its second Duchenne’s drug by year’s end
Stat
Sarepta Therapeutics
Duchenne Muscular Dystrophy
FDA
golodirsen
Exondys 51
Flag link:
Anthem reverses course, agrees to cover Sarepta's Duchenne drug
Anthem reverses course, agrees to cover Sarepta's Duchenne drug
BioPharma Dive
Anthem
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Exondys 51
Flag link:
3 Biotech Stocks That Could Soar in September
3 Biotech Stocks That Could Soar in September
Motley Fool
biotech
fitusiran
Alnylam
PTC Therapeutics
Translarna
Sarepta
Exondys 51
Flag link:
BioMarin may have lost the battle in DMD rivalry, but it won a $35M argument with Sarepta
BioMarin may have lost the battle in DMD rivalry, but it won a $35M argument with Sarepta
Endpoints
Biomarin
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Exondys 51
Flag link:
Payor Re-Evaluation On Exondys Positive For Sarepta
Payor Re-Evaluation On Exondys Positive For Sarepta
Yahoo/Benzinga
payers
Exondys 51
Duchenne Muscular Dystrophy
Sarepta Therapeutics
Flag link:
Sarepta May Have More Upside After Sales Data
Sarepta May Have More Upside After Sales Data
Seeking Alpha
Sarepta
Duchenne Muscular Dystrophy
Exondys 51
eteplirsen
Flag link:
Sarepta eyes a different approach to Duchenne: gene therapy
Sarepta eyes a different approach to Duchenne: gene therapy
Bizjournals.com
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Exondys 51
gene therapy
Flag link:
WSJ’s editorial page puts the blame over Exondys 51 controversy on insurers, regulators and reporters
WSJ’s editorial page puts the blame over Exondys 51 controversy on insurers, regulators and reporters
Endpoints
WSJ
Exondys 51
Duchenne Muscular Dystrophy
Sarepta Therapeutics
Flag link:
For Sarepta, Goldman Adopts 'Wait-And-Watch Approach' On Exondys 51
For Sarepta, Goldman Adopts 'Wait-And-Watch Approach' On Exondys 51
Yahoo/Benzinga
Sarepta Therapeutics
Exondys 51
Duchenne Muscular Dystrophy
Flag link:
Will Insurers Pay For Sarepta’s DMD Drug?
Will Insurers Pay For Sarepta’s DMD Drug?
Barron's
Sarepta
Duchenne Muscular Dystrophy
Exondys 51
Medicaid
payers
insurers
Flag link:

Pages